Research programme: cancer therapeutics - Adamis Pharmaceuticals CorporationAlternative Names: APC-200; APC-300; CPC-200; CPC-300; Prost-aid; Prost-guard; Prost-vance
Latest Information Update: 09 Jan 2014
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Adamis Pharmaceuticals Corporation
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Oxidoreductase inhibitors; Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer; Prostate cancer